Risk Model of Cognitive Impairment in Diabetes
Early Diagnosis and Risk Evaluation of Mild Cognitive Impairment in Diabetes
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Bi Yan, MD, PhD
- Phone Number: +8602583106666
- Email: biyan@nju.edu.cn
Study Locations
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210008
- Recruiting
- Division of Endocrinology, the Affiliated Drum Tower Hospital of Nanjing University
-
Contact:
- Yan Bi, MD,PhD
- Email: biyan@gmail.com
-
Contact:
- Zhou Zhang, MD,PhD
- Email: zhangzhou@smail.nju.edu.cn
-
Principal Investigator:
- Zhou Zhang, PhD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients with type 2 diabetes mellitus ;
- Aged:40 -80 years ;
- Montreal Cognitive Assessment Scale (MoCA) scores 19 - 30;
Exclusion Criteria:
- Mini-mental State Examination(MMSE) scores < 24;
- Other dementia related neurological diseases or depression, schizophrenia in the past 2 years;
- Central nervous system diseases, including brain trauma, intracranial hemorrhage, acute cerebral infarction;
- Severe sinusitis, nasal cavity and sinus polyps, skull base or nasopharyngeal tumors and other space occupying lesions, congenital diseases and traumatic history of nose, maxillofacial and skull base affecting olfaction;
- Diabetic acute and chronic complications, including diabetic ketoacidosis, a hyperglycemic hyperosmolar state or severe hypoglycemic coma.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Training cohort
The patients will be divided into the training and validation cohorts with a ratio of 7:3.
The training cohort will be used to screen variables and construct the model.
|
Cognitive assessments and olfactory tests
|
|
Validation cohort
The validation cohort will be used to validate the results obtained using the training cohort.
|
Cognitive assessments and olfactory tests
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The rate of mild cognitive impairment occurrence
Time Frame: 1 year
|
The rate of Montreal Cognitive Assessment(MoCA) scores less than 26 points after 1 year's follow-up.
|
1 year
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Glycaemic control measured by blood test.
Time Frame: 1 day
|
HbA1c
|
1 day
|
|
Physical assessments.
Time Frame: 1 day
|
BMI(body mess index) in kg/m^2
|
1 day
|
|
Olfactory threshold test
Time Frame: 1 day
|
The same odor with 2 different concentrations are given to the participant each time to find out which one is more intense.
(Olfactory software will analyse and give threshold score depending on participant's choice.)
|
1 day
|
|
Olfactory memory test
Time Frame: 1 day
|
PART A: Participants are shown 4 pictures for each odor(10 odors in total). They select what they sniffed. 10 minutes break. PART B: Participants sniff 20 different odors , 10 of which are same odors in PART A. They select the picture and figure out whether the odor is old or new. |
1 day
|
|
Montreal Cognitive Assessment (MoCA) score
Time Frame: 1 day
|
The MoCA is a cognitive screening test designed to assist health professionals in detection of mild cognitive impairment.
|
1 day
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
General Publications
- Zhang Z, Zhang B, Wang X, Zhang X, Yang QX, Qing Z, Zhang W, Zhu D, Bi Y. Olfactory Dysfunction Mediates Adiposity in Cognitive Impairment of Type 2 Diabetes: Insights From Clinical and Functional Neuroimaging Studies. Diabetes Care. 2019 Jul;42(7):1274-1283. doi: 10.2337/dc18-2584. Epub 2019 May 21.
- Zhang Z, Zhang B, Wang X, Zhang X, Yang QX, Qing Z, Lu J, Bi Y, Zhu D. Altered Odor-Induced Brain Activity as an Early Manifestation of Cognitive Decline in Patients With Type 2 Diabetes. Diabetes. 2018 May;67(5):994-1006. doi: 10.2337/db17-1274. Epub 2018 Mar 2.
- Cheng H, Zhang Z, Zhang B, Zhang W, Wang J, Ni W, Miao Y, Liu J, Bi Y. Enhancement of Impaired Olfactory Neural Activation and Cognitive Capacity by Liraglutide, but Not Dapagliflozin or Acarbose, in Patients With Type 2 Diabetes: A 16-Week Randomized Parallel Comparative Study. Diabetes Care. 2022 May 1;45(5):1201-1210. doi: 10.2337/dc21-2064.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- MCImodel2022
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.